CN-122017053-A - Application of linoleic acid as biomarker and kit for detecting biomarker

Abstract

The invention discloses application of linoleic acid as a biomarker and a kit for detecting the biomarker, and belongs to the technical field of medical detection. The model takes the content level of a biomarker as an input variable to construct a diagnosis model, the biomarker is linoleic acid, and the model uses an equation of score=2.09 x linoleic acid content level/1000-9.399. In the crowd of coronary heart disease, linoleic acid is obviously higher than a non-hyperlipidemia group in patients with hyperlipidemia, the established diagnosis model has good sensitivity and specificity, and the provided kit can realize diagnosis and prognosis monitoring of the hyperlipidemia and guide lipid nutrition intake in the treatment process of the patients.

Inventors

• LIU YU
• ZHAO FURONG
• CAO HAIYAN
• WANG SHUANG
• Ji Xuyao

Assignees

• 哈尔滨医科大学

Dates

Publication Date

20260512

Application Date

20241112

Claims (6)

1. 1. The application of the biomarker linoleic acid is characterized in that the biomarker is applied to a diagnosis model for diagnosing hyperlipidemia, the model takes the content level of the biomarker as an input variable, a diagnosis model is constructed, the biomarker is linoleic acid, and the model uses an equation that the score=2.09 x the content level of the linoleic acid/1000-9.399.
2. 2. The use of linoleic acid as a biomarker according to claim 1, wherein the model diagnosis score evaluates a cut-off value for hyperlipidemia of 0.45, diagnoses hyperlipidemia when the score is greater than or equal to 0.45, and diagnoses non-hyperlipidemia when the score is less than 0.45.
3. 3. A kit for detecting linoleic acid as a biomarker, the kit comprising reagents for detecting linoleic acid.
4. 4. The kit for detecting linoleic acid as claimed in claim 3, wherein the kit is a high performance liquid chromatography tandem mass spectrometry kit.
5. 5. The kit for detecting linoleic acid as claimed in claim 4, wherein the control sample of the kit is derived from patients suffering from hyperlipidemia and non-hyperlipidemia in coronary heart disease, and the sample is serum or plasma.
6. 6. The kit for detecting linoleic acid as claimed in claim 4, wherein the type of linoleic acid detected by the kit is the sum of esterified and non-esterified linoleic acid in blood.

Description

Application of linoleic acid as biomarker and kit for detecting biomarker Technical Field The invention relates to the technical field of medical detection, in particular to application of linoleic acid as a biomarker and a kit for detecting the biomarker. Background Cardiovascular disease (cardiovascular disease, CVD) is the most prominent chronic non-infectious disease worldwide that threatens human life health. CVD, which is the main cause of atherosclerosis cardiovascular disease (atherosclerotic cardiovascular disease, ASCVD), is the 1 st cause of death in urban and rural residents in China, accounting for more than 40% of the constitution of the cause of death. In recent years, the ASCVD disease burden of China still continues to increase, and the prevention and control work situation is severe. Many studies have demonstrated that chronic hyperlipidemia can lead to atherosclerosis, increase the incidence and mortality of cardiovascular diseases, and low-density lipoprotein cholesterol (low-density lipoprotein cholesterol, LDL-C) is a primary target for ASCVD pathogenicity risk factors and lipid intervention, and can significantly reduce the risk of ASCVD onset and death, and thus lipid management can be rendered ineffective. The clinical diagnosis classification of hyperlipidemia is based on the content level of total cholesterol and triglyceride, the primary target point for intervention judgment is LDL-C, and the preferred strategy for lipid lowering treatment is reasonable diet, moderately increasing physical activity, controlling weight, stopping smoking, limiting drinking and the like, wherein the reasonable diet has great influence on the hyperlipidemia, so that a biomarker is needed, which can assist diagnosis and prognosis judgment of hyperlipidemia and guide patients to reasonably take lipid nutrition. Fatty acids are a class of compounds consisting of three elements, carbon, hydrogen, and oxygen, and are the main components of neutral fats, phospholipids, and glycolipids. Fatty acids in blood exist in esterified and free forms, with esterified forms being predominantly in the form of triglycerides and lipids. Studies have shown that the concentration of fatty acids in blood is a potential biomarker for dietary fat intake, and that fatty acids, palmitic acid, conjugated linoleic acid in infants at various ages are positively correlated with fat and milk consumption, and that the n-6/n-3, arachidonic Acid (AA)/eicosapentaenoic acid (EPA), AA/docosahexaenoic acid (DHA), AA/(epa+dha) and n-3 index (epa+dha) 4 FA ratios in serum phospholipids are significantly reduced after adult lipid lowering diets. Therefore, the fatty acid compound is the biomarker which is most likely to achieve the simultaneous diagnosis, prognosis judgment and diet guidance of the hyperlipidemia, and at present, no rapid and efficient kit and diagnostic model aiming at the detection requirements exist on the market, so that the effective intervention of the hyperlipidemia and the diet therapy guidance of the lipid are seriously hindered. Disclosure of Invention The application aims to provide an application of taking linoleic acid as a biomarker and a kit for detecting the biomarker, and in the population suffering from coronary heart disease, through researching patients suffering from hyperlipidemia and non-hyperlipidemia, detecting various types of fatty acids in plasma or serum of a patient by adopting a high performance liquid chromatography-tandem mass spectrometry method, screening out potential disease markers by adopting a metabonomics method, establishing a diagnosis model, further selecting another group of sample queues, and verifying the biomarkers by using a kit product. The results show that linoleic acid is significantly higher in diagnosis of patients with hyperlipidemia than in non-hyperlipidemia patients, and more particularly, the inventors found that high levels of linoleic acid have good sensitivity and specificity when used for diagnosis of hyperlipidemia, and thus can be used as a biomarker for diagnosis, prognosis monitoring of hyperlipidemia, to solve the problems set forth in the background art described above. In order to achieve the above purpose, the present invention provides the following technical solutions: The application of the biomarker which is linoleic acid is used for a diagnosis model for diagnosing hyperlipidemia, the model takes the content level of the biomarker as an input variable to construct a diagnosis model, the biomarker is linoleic acid, and the model uses an equation of score = 2.09 x linoleic acid content level/1000-9.399. As a still further preferable mode of the invention, the model diagnosis score evaluation hyperlipidemia cutoff value is 0.45, and when the score is not less than 0.45, hyperlipidemia is diagnosed, and when the score is less than 0.45, non-hyperlipidemia is diagnosed. As a still further preferable mode of the invention, the model diagnosis score evalu